Hodgkin Lymphoma Archives

AACR: Monday’s Stars Include Affimed, Hoth and Blueprint

American Association for Cancer Research (AACR), Antibodies, Checkpoint Inhibitors, Clinical Trials, DNA, Efficacy Data, Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC), Hodgkin Lymphoma, Microsatellite instability-high (MSI-H) cancer, Non-Hodgkin Lymphoma, PD-1/PD-L1 inhibitors, R&D, Solid Tumors, Therapeutics

The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans, with hundreds of presentations on cutting-edge cancer research. The presentations run the gamut from preclinical studies to late-stage clinical trials. BioSpace looks at some of the preclinical and early-stage studies presented.

FDA Accepts Supplemental Biologics License Application and Grants Priority Review for Adcetris in Frontline Advanced Hodgkin Lymphoma

Breakthrough Therapy Status, Clinical Trials, FDA/Regulatory, Hodgkin Lymphoma, Priority Review Status, Supplemental New Drug Application (sNDA)

Normal immune cells that live near milk ducts in healthy breast tissue may play a key role in helping early breast cancer cells leave the breast for other parts of the body, researchers say.

Keytruda EU Approval for Hematologic Malignancy

Approvals, European Commission, FDA/Regulatory, Hodgkin Lymphoma, Monoclonal Antibodies, PD-1 Inhibitors

The European Commission approved Merck’s anti-PD-1 therapy Keytruda for treating adult patients with relapsed or refractory classical Hodgkin lymphoma.